Triple-negative breast cancer is defined as being negative for the estrogen receptor, progesterone receptor, and HER2 biomarkers. Because of this, targeted therapies for these biomarkers do not work for triple-negative MBC. As a result, triple-negative MBC is commonly only treated with chemotherapy. However, researchers are beginning to understand that triple-negative MBC expresses other biomarkers that can be treated with targeted therapy.
Read more about targeted therapy, and learn about potential targeted therapies for triple-negative MBC.
Targeted Therapy and Triple-Negative MBC
- ASCO: Understanding Targeted Therapy
- Cancer Connect: Update on Strategies to Improve Treatment for Triple-Negative Breast Cancer
Target: PD-L1
- Metastatic Trial Talk: Immune Checkpoint Inhibitors
- Breastcancer.org: Pembrolizumab (Keytruda®)
Target: Trop2
- National Cancer Institute: Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer
- Breastcancer.org: Sacituzumab Govitecan-hziy (Trodelvy®)
Target: Androgen Receptors
- Journal Article: Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer
- Breast Cancer Research Foundation: Possible Dual Treatment for Triple-Negative Breast Cancer
- Cancer Connect: Androgen Receptor May Contribute to Some Cases of Triple-Negative Breast Cancer
Target: AKT
- Journal Article: AKT Inhibition Improves Overall Survival in Triple-Negative Breast Cancer
- ASCO: AKT Targeted Therapy Needs Further Research for TNBC
Metastatic Trial Search: Trials for Triple-Negative MBC Targets
- Triple-Negative MBC Trials
- PD-1/PD-L1 Trials
- Trop2 Trials
- Androgen Receptor Trials
- AKT Trials
- Solid Tumor Trials: May Include Triple-Negative MBC
Last Modified on September 26, 2023